LONDON, July 16, 2024 – Huma, the UK-based healthcare AI company often dubbed the “Shopify of digital health,” has secured $80 million in Series D funding, bringing its total funding to over $300 million.
Huma specializes in developing modular platforms utilized by more than 3,000 hospitals and clinics globally. With a user base of over 35 million screened individuals and 4 million registered users in healthcare, Huma has facilitated over 800 studies involving approximately 1 million participants.
Key applications of Huma’s technology include virtual care tools for digital-first screening, population health initiatives, and remote patient monitoring (RPM). Additionally, Huma supports companion apps aiding patients through treatment and drug therapies, as well as digital clinical trials, including decentralized trials aimed at accelerating medical research.
The company operates in major national healthcare projects across the US, UK, Germany, Greece, and Saudi Arabia, collaborating extensively with leading pharmaceutical companies.
In conjunction with its Series D funding, Huma has launched the Huma Cloud Platform. This technology ecosystem not only supports Huma’s own digital health initiatives but also empowers others to efficiently launch and scale their projects. The platform aims to reduce the development and launch time of digital health projects from years to just a few days, leveraging its regulatory status as the first configurable, disease-agnostic platform recognized by FDA Class II, EuMDR Class IIb, and Saudi FDA Class C.
The Huma Cloud Platform includes a Software Development Kit (SDK) enabling accelerated development of applications and integration of functionalities into existing solutions.
Dan Vahdat, Founder and CEO of Huma, commented on the platform’s role, stating, “We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. They remain consistent and will help us transition medicine from being reactive to proactive.”
The Series D funding round saw participation from new and existing strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, and Leaps by Bayer.
Looking forward, Huma aims to leverage its Huma Cloud Platform and advanced AI models to expand its impact in digital-first care and research initiatives, supporting startups and enterprises in deploying necessary digital solutions effectively.
Related topics:
- Health Advocates Challenge Philip Morris Over IQOS Launch in the U.S.
- Bread That is Not Ultra-Processed: A Guide to Healthy Options
- Oral Health Providers Rally Behind Canadian Dental Care Plan Amid Controversy
